Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367370 | 0.88 | PTGS2 (0.42) | MAOBMEN1KMT2ALMNAPTGS2 | |
| SCHEMBL16367408 | 0.85 | ACHE (0.44) | MEN1KMT2ALMNAALDH1A1NPC1 | |
| SCHEMBL16367373 | 0.82 | MAOB (0.44) | MAOBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL16367382 | 0.79 | POLB (0.48) | MEN1KMT2ALMNACA2ALDH1A1 | |
| SCHEMBL2240871 | 0.79 | IDO1 (0.42) | MEN1KMT2ALMNACA2 | |
| SCHEMBL16367405 | 0.78 | TSHR (0.44) | MEN1KMT2ALMNACA2ALDH1A1 | |
| SCHEMBL27938283 | 0.78 | MEN1 (0.44) | MEN1KMT2ALMNACA2NPC1 | |
| SCHEMBL16390172 | 0.76 | MAOB (0.46) | MAOBMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL15118477 | 0.76 | CYP19A1 (0.41) | MEN1KMT2ACA2 | |
| SCHEMBL15607952 | 0.74 | MAOB (0.36) | MAOBMEN1KMT2ALMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | MAOB 108/4885MEN1 2288/4885KMT2A 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.